> Skip to content
FEATURED:
  • An Update for Readers on Our New Nonprofit Status
Sign In
  • Latest
  • Advice
  • Opinion
  • Webinars
  • Data
  • Grants
  • Magazine
  • Store
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
  • Jobs
    • Find a Job
    • Post a Job
    • Find a Job
    • Post a Job
Sign In
  • Latest
  • Advice
  • Opinion
  • Webinars
  • Data
  • Grants
  • Magazine
  • Store
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
  • Jobs
    • Find a Job
    • Post a Job
    • Find a Job
    • Post a Job
  • Latest
  • Advice
  • Opinion
  • Webinars
  • Data
  • Grants
  • Magazine
  • Store
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
  • Jobs
    • Find a Job
    • Post a Job
    • Find a Job
    • Post a Job
Sign In
ADVERTISEMENT
Individual Giving
  • Twitter
  • LinkedIn
  • Show more sharing options
Share
  • Twitter
  • LinkedIn
  • Email
  • Facebook
  • Copy Link URLCopied!
  • Print

Tim Ferriss on Giving for Psychedelic Research: It’s Personal

By  Marc Gunther
April 30, 2019
The loss of loved ones to addiction and his own struggles with depression and anxiety drive author and investor Tim Ferriss’s giving.
Drew Kelly
The loss of loved ones to addiction and his own struggles with depression and anxiety drive author and investor Tim Ferriss’s giving.

For Tim Ferriss, the best-selling author, podcaster, and investor, the decision to devote his philanthropy to research into psychedelic drugs is built on a solid foundation of peer-reviewed science. “I’ve spent hundreds of hours interacting with researchers to get a better understanding of the science,” he says.

It’s also deeply personal. Ferriss’s best friend from childhood died of a fentanyl overdose. An aunt, after injuring her shoulder, became addicted to Percocet and alcohol and died last year. Recently, Ferriss decided to help fund research at John Hopkins to see if psilocybin-assisted therapy could treat opioid addiction.

We’re sorry. Something went wrong.

We are unable to fully display the content of this page.

The most likely cause of this is a content blocker on your computer or network. Please make sure your computer, VPN, or network allows javascript and allows content to be delivered from v144.philanthropy.com and chronicle.blueconic.net.

Once javascript and access to those URLs are allowed, please refresh this page. You may then be asked to log in, create an account if you don't already have one, or subscribe.

If you continue to experience issues, contact us at 202-466-1032 or help@chronicle.com

For Tim Ferriss, the best-selling author, podcaster, and investor, the decision to devote his philanthropy to research into psychedelic drugs is built on a solid foundation of peer-reviewed science. “I’ve spent hundreds of hours interacting with researchers to get a better understanding of the science,” he says.

It’s also deeply personal. Ferriss’s best friend from childhood died of a fentanyl overdose. An aunt, after injuring her shoulder, became addicted to Percocet and alcohol and died last year. Recently, Ferriss decided to help fund research at John Hopkins to see if psilocybin-assisted therapy could treat opioid addiction.

What’s more, Ferriss himself struggled with depression and anxiety as a college student at Princeton. He tried “magic mushrooms,” which contain psilocybin, and found relief. “I was able to finally see things clearly,” he says, “to appreciate all of the incredible chance blessings that I experienced in my life.”

Ferriss, who is now 42, is quick to caution that no one should experiment with illegal drugs under uncontrolled circumstances. But like many, if not most, of the donors to psychedelic science, his passion is driven both by the head and the heart. Usona founder Bill Linton, Cody Swift of the Riverstyx Foundation, and David Bronner, who leads Dr. Bronner’s, which makes organic personal-care products, have all experienced or seen up close the healing potential of psychedelics.

Donors are also motivated because, they say, conventional treatments for the pain caused by PTSD, depression, anxiety, and addiction often fall short.

ADVERTISEMENT

Drug overdoses killed more than 70,000 Americans in 2017, which is more than the number who died during the entire Vietnam War, Ferriss notes.

“These compounds are by no means a panacea,” Ferriss says. “But they show tremendous promise for serious conditions that currently have few or no effective treatments.”

Ferriss has formed a foundation and pledged $2 million of his own money to fund psychedelic science. “Having done a few years of due diligence,” he adds, “I’ve decided to push all my chips in.”

A version of this article appeared in the May 1, 2019, issue.
We welcome your thoughts and questions about this article. Please email the editors or submit a letter for publication.
Fundraising from Individuals
Marc Gunther
Marc Gunther is a veteran journalist, speaker, and writer who reported on business and sustainability for many years. Since 2015, he has been writing about foundations, nonprofits and global development on his blog, Nonprofit Chronicles.
ADVERTISEMENT
ADVERTISEMENT

Related Content

  • With Government Skittish About Psychedelics, Philanthropy Funds Promising Research
  • Explore
    • Latest Articles
    • Get Newsletters
    • Advice
    • Webinars
    • Data & Research
    • Magazine
    • Chronicle Store
    • Find a Job
    Explore
    • Latest Articles
    • Get Newsletters
    • Advice
    • Webinars
    • Data & Research
    • Magazine
    • Chronicle Store
    • Find a Job
  • The Chronicle
    • About Us
    • Work at the Chronicle
    • User Agreement
    • Privacy Policy
    • California Privacy Policy
    • Gift-Acceptance Policy
    • Site Map
    • DEI Commitment Statement
    The Chronicle
    • About Us
    • Work at the Chronicle
    • User Agreement
    • Privacy Policy
    • California Privacy Policy
    • Gift-Acceptance Policy
    • Site Map
    • DEI Commitment Statement
  • Customer Assistance
    • Contact Us
    • Advertise With Us
    • Post a Job
    • Reprints & Permissions
    • Do Not Sell My Personal Information
    Customer Assistance
    • Contact Us
    • Advertise With Us
    • Post a Job
    • Reprints & Permissions
    • Do Not Sell My Personal Information
  • Subscribe
    • Individual Subscriptions
    • Organizational Subscriptions
    • Subscription & Account FAQ
    • Manage Newsletters
    • Manage Your Account
    Subscribe
    • Individual Subscriptions
    • Organizational Subscriptions
    • Subscription & Account FAQ
    • Manage Newsletters
    • Manage Your Account
1255 23rd Street, N.W. Washington, D.C. 20037
© 2023 The Chronicle of Philanthropy
  • twitter
  • youtube
  • pinterest
  • facebook
  • linkedin